Valuation: Keymed Biosciences Inc.

Market Cap 20.54B 24.05B 3.07B 2.72B 2.54B 2.32B 4.35B 295B 4.42B 30.74B 11.91B 150B 11.51B 11.26B 485B P/E 2026 *
25.5x
P/E 2027 * 1,434x
Enterprise Value 19.41B 22.74B 2.9B 2.57B 2.4B 2.19B 4.11B 279B 4.18B 29.06B 11.26B 142B 10.88B 10.64B 458B EV / Sales 2026 *
11.5x
EV / Sales 2027 * 9.13x
Free-Float
74.84%
Yield 2026 *
-
Yield 2027 * -
1 day+2.45%
1 week+3.89%
1 month+8.66%
3 months+15.27%
6 months+34.35%
Current year+52.57%
1 week 72.3
Extreme 72.3
82.4
1 month 71
Extreme 71
82.4
Current year 44.66
Extreme 44.66
89.75
1 year 44.66
Extreme 44.66
89.75
3 years 26.6
Extreme 26.6
89.75
5 years 16.9
Extreme 16.9
89.75
10 years 16.9
Extreme 16.9
89.75
Manager TitleAgeSince
Chief Executive Officer 52 22/04/2018
Corporate Officer/Principal 61 02/03/2021
Corporate Secretary - 28/03/2022
Director TitleAgeSince
Chairman 52 22/04/2018
Director/Board Member 61 02/03/2021
Director/Board Member 52 20/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
13/06/25
Moonshot Holdings Ltd.
OtherCompany 21,600,000 7.7216%
11/06/25
Moonshot Holdings Ltd.
OtherCompany 18,800,000 6.7206%
15/09/23
Moonshot Holdings Ltd.
OtherCompany 114,500 0.0409%
Change 5-day change 1-year change 3-year change Capi.($)
+2.45%+3.89%+9.83%+63.43% 3.06B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average +0.20%+2.16%+50.87%+145.19% 39.99B
Weighted average by Cap. +0.19%+1.85%+59.68%+145.15%

Financials

2026 *2027 *
Net sales 1.68B 1.97B 251M 223M 208M 190M 356M 24.18B 362M 2.52B 975M 12.32B 943M 922M 39.69B 2.15B 2.51B 320M 284M 266M 242M 455M 30.85B 462M 3.21B 1.24B 15.72B 1.2B 1.18B 50.64B
Net income 672M 788M 100M 89.14M 83.26M 75.93M 142M 9.67B 145M 1.01B 390M 4.93B 377M 369M 15.87B -14.18M -16.61M -2.12M -1.88M -1.76M -1.6M -3M -204M -3.05M -21.22M -8.22M -104M -7.95M -7.77M -335M
Net Debt -1.12B -1.32B -168M -149M -139M -127M -238M -16.15B -242M -1.68B -651M -8.22B -629M -616M -26.5B -935M -1.1B -140M -124M -116M -106M -198M -13.44B -201M -1.4B -542M -6.85B -524M -513M -22.07B
Logo Keymed Biosciences Inc.
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
1,768
Date Price Change Volume
30/09/26 HK$81.55 +2.45% 2,630,600
29/09/26 HK$79.60 +8.82% 4,260,252
28/09/26 HK$73.15 -2.40% 2,244,500
25/09/26 HK$74.95 +1.22% 600,500
24/09/26 HK$74.05 -5.67% 1,392,500
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
69.71CNY
Average target price
88.83CNY
Spread / Average Target
+27.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2162 Stock